AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Pituitary-specific positive transcription factor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P28069

UPID:

PIT1_HUMAN

Alternative names:

Growth hormone factor 1

Alternative UPACC:

P28069; O75757; Q15132; Q15133; Q9UD34; Q9UEL3

Background:

Pituitary-specific positive transcription factor 1, also known as Growth hormone factor 1, plays a pivotal role in the development of the anterior pituitary gland. It specifically binds to the consensus sequence 5'-TAAAT-3', activating growth hormone and prolactin genes. This transcription factor is crucial for the specification of lactotrope, somatotrope, and thyrotrope phenotypes, essential for normal pituitary function.

Therapeutic significance:

The protein is linked to Combined Pituitary Hormone Deficiency (CPHD1), characterized by growth hormone, prolactin, and thyroid-stimulating hormone deficiencies. Understanding the role of Pituitary-specific positive transcription factor 1 could open doors to potential therapeutic strategies for treating CPHD1, offering hope for patients suffering from severe growth deficiency and intellectual disability.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.